Personalized Medicine Does Not Fit In FDA's Current Scheme, Experts Say
This article was originally published in The Gray Sheet
FDA's "old regulatory schemas" will not work for genetic and genomic testing and the broader field of personalized medicine, FDA Commissioner Margaret Hamburg admits
You may also be interested in...
An inaugural review of the diagnostics sector newly published by PricewaterhouseCoopers contends that growing interest in personalized medicine is a key factor driving partnering deals between pharmaceutical companies and diagnostics developers
UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.